The study of Sanders et al. highlights the potential of Nectin-4 as both a prognostic marker and a therapeutic target and also raises the possibility of Enfortumab Vedotin (EV), an antibody–drug conjugate targeting Nectin-4, being explored in future trials for selected HNSCC cases. This evidence concerns the gene NECTIN4 and head and neck squamous cell carcinoma.